PolyPid (PYPD) Competitors $2.75 +0.05 (+1.85%) As of 03:30 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PYPD vs. MGRM, FONR, NSPR, SRTS, MLSS, ZYXI, CTSO, ICCM, VANI, and INOShould you be buying PolyPid stock or one of its competitors? The main competitors of PolyPid include Monogram Orthopaedics (MGRM), FONAR (FONR), InspireMD (NSPR), Sensus Healthcare (SRTS), Milestone Scientific (MLSS), Zynex (ZYXI), Cytosorbents (CTSO), IceCure Medical (ICCM), Vivani Medical (VANI), and Inovio Pharmaceuticals (INO). These companies are all part of the "medical equipment" industry. PolyPid vs. Monogram Orthopaedics FONAR InspireMD Sensus Healthcare Milestone Scientific Zynex Cytosorbents IceCure Medical Vivani Medical Inovio Pharmaceuticals Monogram Orthopaedics (NASDAQ:MGRM) and PolyPid (NASDAQ:PYPD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, community ranking and risk. Which has stronger valuation and earnings, MGRM or PYPD? Monogram Orthopaedics has higher revenue and earnings than PolyPid. Monogram Orthopaedics is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonogram Orthopaedics$365.00K253.31-$13.74M-$0.46-5.70PolyPidN/AN/A-$29.02M-$4.97-0.55 Does the MarketBeat Community favor MGRM or PYPD? PolyPid received 29 more outperform votes than Monogram Orthopaedics when rated by MarketBeat users. Likewise, 80.00% of users gave PolyPid an outperform vote while only 75.00% of users gave Monogram Orthopaedics an outperform vote. CompanyUnderperformOutperformMonogram OrthopaedicsOutperform Votes375.00% Underperform Votes125.00% PolyPidOutperform Votes3280.00% Underperform Votes820.00% Which has more risk & volatility, MGRM or PYPD? Monogram Orthopaedics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, PolyPid has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500. Do insiders and institutionals have more ownership in MGRM or PYPD? 0.4% of Monogram Orthopaedics shares are owned by institutional investors. Comparatively, 26.5% of PolyPid shares are owned by institutional investors. 28.1% of Monogram Orthopaedics shares are owned by company insiders. Comparatively, 24.7% of PolyPid shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media prefer MGRM or PYPD? In the previous week, PolyPid had 4 more articles in the media than Monogram Orthopaedics. MarketBeat recorded 7 mentions for PolyPid and 3 mentions for Monogram Orthopaedics. PolyPid's average media sentiment score of 1.07 beat Monogram Orthopaedics' score of 0.70 indicating that PolyPid is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monogram Orthopaedics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PolyPid 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate MGRM or PYPD? Monogram Orthopaedics presently has a consensus target price of $5.40, suggesting a potential upside of 106.11%. PolyPid has a consensus target price of $11.33, suggesting a potential upside of 312.12%. Given PolyPid's higher possible upside, analysts plainly believe PolyPid is more favorable than Monogram Orthopaedics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monogram Orthopaedics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50PolyPid 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Is MGRM or PYPD more profitable? Monogram Orthopaedics' return on equity of -130.90% beat PolyPid's return on equity.Company Net Margins Return on Equity Return on Assets Monogram OrthopaedicsN/A -130.90% -106.38% PolyPid N/A -624.10%-129.28% SummaryPolyPid beats Monogram Orthopaedics on 9 of the 16 factors compared between the two stocks. Remove Ads Get PolyPid News Delivered to You Automatically Sign up to receive the latest news and ratings for PYPD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PYPD vs. The Competition Export to ExcelMetricPolyPidSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.03M$4.08B$5.28B$7.36BDividend YieldN/A39.51%5.11%4.32%P/E Ratio-0.5527.7721.6317.68Price / SalesN/A49.01371.0992.89Price / CashN/A51.0838.1534.64Price / Book3.675.836.373.94Net Income-$29.02M$67.64M$3.20B$247.45M7 Day Performance9.56%-0.76%1.79%0.48%1 Month Performance-6.91%-3.81%-9.41%-7.08%1 Year Performance-41.98%14.16%9.61%-0.35% PolyPid Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PYPDPolyPid2.7835 of 5 stars$2.75+1.9%$11.33+312.1%-40.0%$28.03MN/A-0.5580Analyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive NewsMGRMMonogram Orthopaedics2.7128 of 5 stars$2.52+0.8%$5.40+114.3%+4.2%$88.93M$364,999.00-5.3628Short Interest ↑News CoverageGap DownFONRFONAR1.3147 of 5 stars$13.00-2.8%N/A-27.9%$80.64M$101.57M11.30480Short Interest ↑NSPRInspireMD2.0651 of 5 stars$2.59-1.9%$4.75+83.4%+8.4%$76.90M$7.01M-3.4550Gap UpSRTSSensus Healthcare2.4907 of 5 stars$4.48+0.4%$13.00+190.2%+45.3%$73.90M$41.81M11.2040Positive NewsMLSSMilestone Scientific1.6246 of 5 stars$0.89+2.3%$1.25+40.4%+65.5%$69.32M$8.88M-12.7130Analyst ForecastNews CoverageGap UpZYXIZynex3.0026 of 5 stars$2.16flat$10.25+374.5%-81.6%$65.29M$192.35M14.40770Analyst ForecastHigh Trading VolumeCTSOCytosorbents1.9951 of 5 stars$0.99+2.1%$4.67+371.1%+16.5%$61.91M$35.59M-2.75220Positive NewsGap UpICCMIceCure Medical2.422 of 5 stars$1.11-2.6%$2.50+125.2%-17.0%$61.61M$3.29M-3.8360Positive NewsVANIVivani Medical2.801 of 5 stars$1.02+6.3%$4.00+292.2%-49.0%$60.42MN/A-2.2720Analyst ForecastShort Interest ↑News CoverageGap UpINOInovio Pharmaceuticals3.3195 of 5 stars$1.58+1.3%$12.20+672.2%-84.0%$57.93M$217,756.00-0.40320Short Interest ↑High Trading Volume Remove Ads Related Companies and Tools Related Companies Monogram Orthopaedics Alternatives FONAR Alternatives InspireMD Alternatives Sensus Healthcare Alternatives Milestone Scientific Alternatives Zynex Alternatives Cytosorbents Alternatives IceCure Medical Alternatives Vivani Medical Alternatives Inovio Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PYPD) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredIf Gold Is ‘Stalling,’ Why Are Banks Hoarding Billions In Secret?Prosperity was something every American family could build, protect, and pass down. Because that's what legacy...Colonial Metals | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredCould this be my downfall?I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolyPid Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PolyPid With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PYPD Stock Free PYPD Stock Alerts